Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.

Christine KochMarkus GöllerEckart SchottOliver WaidmannMark Op den WinkelPhilipp PaprottkaStephan ZangosThomas VoglWolf Otto BechsteinStefan ZeuzemFrank T KolligsJörg Trojan

Published in: Cancers (2021)

Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
replacement therapy